Last updated: February 24, 2026
What is NDC 70000-0211?
NDC 70000-0211 refers to Amifampridine (3,4-DAP), a drug approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). It is marketed under the brand name Firdapse by Catalyst Pharmaceuticals.
Market Size and Patient Population
Estimated Patient Population
- LEMS prevalence: Approximately 3,000 to 4,000 cases in the U.S.[^1]
- Treatment eligibility: Firdapse is indicated for adult patients with LEMS who have a confirmed diagnosis. Most cases are diagnosed in neuromuscular clinics, with a roughly 80% treatment adherence rate.
Market Penetration
- As of 2022, Catalyst Pharmaceuticals reported sales from approximately 2,500 patients treated with Firdapse in the United States.
- Estimated annual prescriptions: 3,000 to 4,000 units (considering dosage and treatment cycles).
Competitive Landscape
- Alternative treatments: 3,4-DAP, compounded formulations (off-label use), and other symptomatic therapies.
- Regulatory status: Firdapse holds FDA approval, while compounded 3,4-DAP has no FDA approval but is used off-label in some regions.
Pricing Overview
Current Wholesale and Retail Prices
- Average wholesale price (AWP): Approximately $55,000 to $60,000 per year per patient.[^2]
- List price (per unit dose): Roughly $6 to $7 per 50 mg tablet.
- Monthly treatment cost: Estimated at $4,500 to $5,000, depending on dosing.
Pricing by Market Segment
| Segment |
Price Range |
| Wholesale (per unit) |
$6-$7 |
| Retail (per month) |
$4,500-$5,000 |
| Annual per-patient cost |
$55,000-$60,000 |
Revenue Projections
Near-term (Next 2 years)
- Sales volume: Stable at approximately 2,500-3,000 patients.
- Revenue: Estimated at $125 million-$180 million annually, assuming $50,000 per patient.
Mid-term (3-5 years)
- Market expansion potential: Greater diagnosis rates and increased physician adoption could raise treatment numbers by 10-15%.
- Projected revenues: $135 million-$200 million, with possible slight price increases or formulary access expansion.
Long-term (5+ years)
- Market maturity: Likely plateau around 4,000 treated patients.
- Price adjustments: Potential for slight price erosion due to patent issues or biosimilar entry in alternative markets, but unlikely in the US due to exclusivity and limited competition.
Regulatory and Policy Impact
- Patent exclusivity: Firdapse's patent expires in 2027, with data exclusivity extending into 2028.
- Impact: Potential for biosimilar or generic competition after patent expiry, reducing prices.
Price Projection Scenarios
| Scenario |
Timeline |
Estimated Price Changes |
Comments |
| Conservative |
2023-2027 |
Price remains stable at current levels |
No competition, steady demand |
| Moderate |
2028-2032 |
Slight reduction of 10-15% due to biosimilar entry |
Expanded market access, reduced average price |
| Aggressive |
2028+ |
Price declines of 30% or more after patent expiry |
High biosimilar activity, increased competition |
Key Takeaways
- The current market for NDC 70000-0211 (Firdapse) remains limited but stable, with revenues around $125-$180 million annually.
- Prices are high due to the rare disease status and limited competition, with annual per-patient costs of approximately $55,000.
- Patent expiry coming in 2027 could lead to significant price erosion over the following five years.
- Market expansion depends heavily on improved diagnosis rates and insurance coverage.
FAQs
What is the main driver of market growth for NDC 70000-0211?
Increased awareness of LEMS and improved diagnosis could expand the treated population, driving growth.
How does the price of Firdapse compare internationally?
International prices vary; some countries pay less due to negotiated pricing and health system differences, but high-cost sharing persists.
What are the risks to price stability?
Entry of biosimilars or generics post-patent expiry, insurance reimbursement challenges, and regulatory changes.
Are there alternative therapies that threaten Firdapse’s market?
Other treatments like compounded 3,4-DAP are used off-label but lack FDA approval, limiting their impact.
What is the expected impact of future regulatory changes?
Potential approval of biosimilars could significantly lower prices, though current exclusivity protections mitigate this risk until 2027.
References
- Autor, M. (2020). Lambert-Eaton Myasthenic Syndrome: Disease overview. Neurology Reports, 14(2), 253–261.
- Catalyst Pharmaceuticals. (2022). Firdapse sales and revenue reports. Retrieved from company filings.
- Food and Drug Administration. (2019). Firdapse (amifampridine) approval notice. FDA.
(Note: This analysis uses publicly available data and estimates; actual current prices and market figures may vary.)
